Tell me about protean biodiagnostics ngs

About Protean BioCorp NGS Testing for Alan's Case

Based on Alan's clinical summary, NGS (Next-Generation Sequencing) testing through Protean BioCorp is being arranged to help identify specific genetic mutations in his tumor that might guide treatment decisions.

What This Means for Alan's Situation

According to the document, Alan is "awaiting comprehensive genomic profiling" through Protean BioCorp. This testing is important because:

• Identifies targetable mutations: The NGS can reveal specific genetic changes in his glioblastoma that might respond to targeted therapies
• Guides treatment selection: Different mutations may respond to different drugs
• Explores clinical trial eligibility: Knowing his tumor's genetic profile helps identify which clinical trials he might qualify for

Current Context in Alan's Care

The document notes that:

• Standard biopsy results are available, but specific molecular details aren't fully detailed in the records
• Alan does not currently qualify for the Niraparib trial at [facility removed]
• The genomic profiling results could potentially open new treatment options

Important Note

The document doesn't provide specific details about Protean BioCorp's particular testing methodology or turnaround times. For detailed information about what this specific NGS panel includes and when results might be available, Alan should discuss this directly with his oncology team at [facility removed].

This genomic testing is a crucial step in identifying whether Alan might be eligible for targeted therapies or clinical trials—which aligns with his and his wife's active search for additional treatment options.